Cargando…

Phase I/IIa trial of androgen deprivation therapy, external beam radiotherapy, and stereotactic body radiotherapy boost for high-risk prostate cancer (ADEBAR)

BACKGROUND: To evaluate the clinical outcomes of combination of androgen deprivation therapy (ADT), whole pelvic radiotherapy (WPRT), and stereotactic body radiotherapy (SBRT) boost in high-risk prostate cancer patients. METHODS: This prospective phase I/IIa study was conducted between 2016 and 2017...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Yeon Joo, Ahn, Hanjong, Kim, Choung-Soo, Kim, Young Seok
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7542889/ https://www.ncbi.nlm.nih.gov/pubmed/33032643 http://dx.doi.org/10.1186/s13014-020-01665-6

Ejemplares similares

Stereotactic body-radiotherapy boost dose of 18 Gy vs 21 Gy in combination with androgen-deprivation therapy and whole-pelvic radiotherapy for intermediate- or high-risk prostate cancer: a study protocol for a randomized controlled, pilot trial
por: Kim, Yeon Joo, et al.
Publicado: (2018)

Androgen deprivation therapy during and after post-prostatectomy radiotherapy in patients with prostate cancer: a case control study
por: Kim, Myong, et al.
Publicado: (2018)

Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost as post-external beam radiotherapy versus conventionally fractionated external beam radiotherapy for localized prostate cancer
por: Phak, Jeong Hoon, et al.
Publicado: (2016)

Simultaneous integrated boost with stereotactic radiotherapy for dominant intraprostatic lesion of localized prostate cancer: a dosimetric planning study
por: Kim, Yeon Joo, et al.
Publicado: (2020)

PROstate Multicentre External beam radioTHErapy Using a Stereotactic boost: the PROMETHEUS study protocol
por: Richardson, Matthew, et al.
Publicado: (2018)

Boost in radiotherapy: external beam sunset, brachytherapy sunrise
por: Maciejewski, Boguslaw
Publicado: (2009)

Treatment of Retinoblastoma: The Role of External Beam Radiotherapy
por: Kim, Joo-Young, et al.
Publicado: (2015)

Combined brachytherapy and external beam radiotherapy without adjuvant androgen deprivation therapy for high-risk prostate cancer
por: Ohashi, Toshio, et al.
Publicado: (2014)

Is there a role for an external beam boost in cervical cancer radiotherapy?(†)
por: Sethi, Rajni A., et al.
Publicado: (2013)

Image-guided, whole-pelvic, intensity-modulated radiotherapy for biochemical recurrence following radical prostatectomy in high-risk prostate cancer patients
por: Byun, Sang Jun, et al.
Publicado: (2018)

Stereotactic ablative body radiotherapy boost for cervical cancer when brachytherapy boost is not feasible
por: Lee, Tae Hoon, et al.
Publicado: (2021)

Effects of statin use on the response duration to androgen deprivation therapy in metastatic prostate cancer
por: Jung, Jaeyoon, et al.
Publicado: (2015)

Radical prostatectomy versus external beam radiotherapy with androgen deprivation therapy for high-risk prostate cancer: a systematic review
por: Heesterman, Berdine L., et al.
Publicado: (2023)

Feasibility of stereotactic radiotherapy for lung lesions and conventional radiotherapy for nodal areas in primary lung malignancies
por: Kim, Yeon Joo, et al.
Publicado: (2018)

Does brachytherapy boost improve survival outcomes in Gleason Grade Group 5 patients treated with external beam radiotherapy and androgen deprivation therapy? A systematic review and meta-analysis
por: Tang, Terence, et al.
Publicado: (2022)

Comparison of radical prostatectomy and external beam radiotherapy in high-risk prostate cancer
por: Chun, Seok-Joo, et al.
Publicado: (2021)

Prostate-specific antigen kinetics and metastasis-free survival in patients treated with external beam radiotherapy combined with high-dose-rate brachytherapy boost and androgen deprivation therapy for localized prostate cancer
por: Miszczyk, Marcin, et al.
Publicado: (2022)

Long-term outcome and toxicity of hypofractionated stereotactic body radiotherapy as a boost treatment for head and neck cancer: the importance of boost volume assessment
por: Lee, Dong Soo, et al.
Publicado: (2012)

Prostate only radiotherapy using external beam radiotherapy: A clinician’s perspective
por: Lee, Jeong Won, et al.
Publicado: (2022)

Testosterone as a Biomarker for Quality of Life (QOL) Following Androgen Deprivation Therapy (ADT) and Stereotactic Body Radiotherapy (SBRT)
por: Shah, Sarthak, et al.
Publicado: (2023)

Impact of Adjuvant Androgen-Deprivation Therapy on Disease Progression in Patients with Node-Positive Prostate Cancer
por: Park, Sejun, et al.
Publicado: (2011)

Prostate-specific antigen kinetics after stereotactic body radiotherapy as monotherapy or boost after whole pelvic radiotherapy for localized prostate cancer
por: Kim, Hun Jung, et al.
Publicado: (2015)

Whole pelvic intensity-modulated radiotherapy for high-risk prostate cancer: a preliminary report
por: Joo, Ji Hyeon, et al.
Publicado: (2013)

Hypofractionated Proton Boost Combined with External Beam Radiotherapy for Treatment of Localized Prostate Cancer
por: Johansson, Silvia, et al.
Publicado: (2012)

Stereotactic body radiotherapy versus conventional/moderate fractionated radiation therapy with androgen deprivation therapy for unfavorable risk prostate cancer
por: Patel, Sagar A., et al.
Publicado: (2020)

The effectiveness and side effects of conformal external beam radiotherapy combined with high-dose-rate brachytherapy boost compared to conformal external beam radiotherapy alone in patients with prostate cancer
por: Smolska-Ciszewska, Beata, et al.
Publicado: (2015)

Stereotactic Ablative Radiotherapy for Oligometastatic Disease in Liver
por: Kim, Myungsoo, et al.
Publicado: (2014)

Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts
por: Kishan, Amar U., et al.
Publicado: (2022)

Factors associated with testosterone recovery after androgen deprivation therapy in patients with prostate cancer
por: Nam, Wook, et al.
Publicado: (2018)

Effects of two different radiotherapies for craniopharyngiomas using stereotactic radiosurgery/ stereotactic radiotherapy or fractionated stereotactic radiotherapy
por: Kamogawa, Misaki, et al.
Publicado: (2022)

Reduction of margins in external beam radiotherapy
por: Kron, Tomas
Publicado: (2008)

Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer
por: Røe, Kathrine, et al.
Publicado: (2012)

Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
por: Amit, Uri, et al.
Publicado: (2019)

Salvage hypofractionated accelerated versus standard radiotherapy for the treatment of biochemical recurrence after radical prostatectomy (SHARE): the protocol of a prospective, randomized, open-label, superiority, multi-institutional trial
por: Park, Geumju, et al.
Publicado: (2021)

The Early Result of Whole Pelvic Radiotherapy and Stereotactic Body Radiotherapy Boost for High-Risk Localized Prostate Cancer
por: Lin, Yu-Wei, et al.
Publicado: (2014)

Whole Pelvic Radiotherapy With Stereotactic Body Radiotherapy Boost vs. Conventionally Fractionated Radiotherapy for Patients With High or Very High-Risk Prostate Cancer
por: Wang, Shih-Chang, et al.
Publicado: (2020)

Dosimetric Comparison of Upfront Boosting With Stereotactic Radiosurgery Versus Intraoperative Radiotherapy for Glioblastoma
por: Sarria, Gustavo R., et al.
Publicado: (2021)

Stereotactic Radiotherapy Boost in Treatment of Persistent Periocular Sebaceous Carcinoma after Surgery
por: Polanowski, Paweł, et al.
Publicado: (2023)

The Efficacy of External Beam Radiotherapy for Airway Obstruction in Lung Cancer Patients
por: Lee, Jeong Won, et al.
Publicado: (2015)

A Survey of Stereotactic Body Radiotherapy in Korea
por: Bae, Sun Hyun, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_gkqk2m7ueg3vr60pemus5p29ef